Vaccines

Innovation for Disease Prevention and Control

Not all vaccines are made the same way, but each plays a vital role in protecting public health. At Adeptio Pharmaceuticals, our teams are pioneering new vaccine technologies with the potential to fight infectious diseases more effectively than ever before. Building on the groundbreaking work of Louis Pasteur, who first linked micro-organisms to infection, we proudly carry forward a 150-year legacy of vaccine innovation. Every day, our scientists invest energy and creativity into developing solutions that allow people to coexist with the many micro-organisms in our environment while defeating those that cause harm.

Vaccines: Pioneering Innovation for Global Health Protection

For more than a century, vaccines have stood as one of the greatest achievements in public health, preventing countless illnesses and saving millions of lives worldwide. At Healthmat Pharmaceuticals, we carry forward this proud legacy by advancing cutting-edge vaccine research and development that seeks not only to stop infectious diseases but also to explore their wider links to chronic health conditions. Our scientists are driven by a simple yet profound mission: to harness the power of immunology and modern technology to keep communities safe, healthy, and prepared for future challenges. We understand that no single approach can protect against every microbe. Pathogens are diverse and constantly evolving, which requires an equally diverse set of vaccine technologies. Our teams at Healthmat Pharmaceuticals leverage a wide spectrum of platforms—ranging from traditional approaches like live-attenuated vaccines to advanced breakthroughs such as mRNA and monoclonal antibodies. This multi-pronged strategy ensures that we are equipped to combat both current threats and those that may emerge in the future.

Our research focuses on designing vaccine antigens—the molecules that trigger the immune system to defend against pathogens. Using a wide range of platforms, we tailor vaccines to target the specific proteins, sugars, or other features that allow microbes to survive and thrive. This diversity of approaches ensures we can confront multiple diseases with precision and speed.

Types of Vaccines We Develop

This involves developing targeted biologics, immune checkpoint therapies, and advanced small-molecule drugs that can recalibrate the immune system without completely suppressing it. By minimizing side effects and enhancing treatment specificity, our aim is to bring lasting relief and quality of life to patients who currently face limited options.

Autoimmune diseases occur when the immune system mistakenly attacks healthy tissues, leading to conditions such as lupus, rheumatoid arthritis, and multiple sclerosis. Our research is focused on therapies that restore immune tolerance—helping the immune system recognize the difference between self and non-self.

Live-attenuated vaccines: Made from weakened viruses, these vaccines train the immune system without causing disease. Yellow fever control and smallpox eradication are landmark achievements of this approach.
Inactivated vaccines: Built from viruses grown in laboratories and then killed, these vaccines (such as polio, rabies, and many influenza vaccines) safely stimulate strong immunity.
Recombinant protein vaccines: By synthesizing only the antigenic protein in the lab, our scientists create targeted vaccines like the recombinant hepatitis B vaccine.
Polysaccharide-based vaccines: Using bacterial sugar coatings (polysaccharides), often linked to proteins for durability, these vaccines expose pathogens to immune attack—key in defending against bacteria such as Haemophilus influenzae type B.
mRNA vaccines: By delivering genetic instructions to cells, mRNA vaccines direct the body to produce antigens that trigger immunity. Our pipeline includes mRNA candidates for influenza, RSV in older adults, and chlamydia.
Monoclonal antibodies: Offering immediate protection, monoclonal antibodies can fill gaps in immunity—particularly for infants or when no vaccine yet exists.
Adjuvanted vaccines: Combining antigens with adjuvants strengthens and prolongs immune responses, enabling broader coverage and improved global supply during outbreaks.

Live-Attenuated Vaccines

Live-attenuated vaccines are among the oldest and most successful approaches to disease prevention. These vaccines use weakened versions of viruses that cannot cause full-blown illness but are strong enough to trigger the body’s immune system to build lasting defenses. Historical triumphs such as the eradication of smallpox and the control of yellow fever stand as powerful testaments to the success of this method. At Healthmat Pharmaceuticals, we continue to refine live-attenuated vaccine development using advanced biotechnology to ensure maximum safety while maintaining robust immunogenicity. This approach helps us preserve the benefits of long-term immunity, often with just one or two doses, making them an indispensable tool in global immunization campaigns.

Inactivated Vaccines

Unlike live-attenuated vaccines, inactivated vaccines use viruses that have been grown in laboratories and then rendered inactive, or killed, before administration. While they cannot replicate inside the body, they effectively train the immune system to recognize and fight the targeted pathogen. Notable examples include vaccines for polio, rabies, and several influenza strains. Healthmat Pharmaceuticals employs state-of-the-art inactivation techniques that maintain the structural integrity of viral antigens. This ensures the immune system recognizes the threat without any risk of infection. These vaccines are particularly valuable in regions where live vaccines may pose risks for immunocompromised individuals, making them a cornerstone of safe, accessible immunization.

Recombinant Protein Vaccines

When only a part of a pathogen is needed to trigger immunity, recombinant protein vaccines provide a precise and effective solution. By synthesizing key antigens in the laboratory through recombinant DNA technology, these vaccines can safely mimic the immune response without exposure to the actual pathogen. Our recombinant hepatitis B vaccine is a successful example of this approach. The flexibility of recombinant technology allows Healthmat Pharmaceuticals to quickly adapt to emerging health threats. By producing specific proteins that elicit strong immune responses, we can design vaccines that are not only safe but also highly targeted. This precision is especially vital in addressing pathogens that mutate frequently or have complex life cycles.

Polysaccharide-Based Vaccines

Certain bacteria, such as Haemophilus influenzae type B, protect themselves with outer coatings made of polysaccharides—complex sugars that help them evade destruction by immune cells. Polysaccharide-based vaccines use these sugars as antigens to “unmask” the bacteria, enabling the immune system to recognize and attack them effectively. To make these vaccines more durable, Healthmat Pharmaceuticals often employs conjugated polysaccharide technology, linking sugars to proteins that enhance immune memory. This combination not only strengthens protection but also ensures that immunity lasts longer, even in young children whose immune systems are still developing. By advancing conjugated vaccine technology, we are broadening the impact of immunization in vulnerable populations worldwide.

mRNA Vaccines

Messenger RNA (mRNA) vaccines represent one of the most groundbreaking scientific advances in recent history. By delivering genetic instructions to cells, mRNA vaccines direct the body to produce antigens that trigger immune protection. Once inside the body, the mRNA is encased in nanoparticles, ensuring stability until it reaches target cells where antigens are produced naturally. At Healthmat Pharmaceuticals, our teams are actively developing mRNA vaccines for influenza, RSV in older adults, and chlamydia, among others. The beauty of this technology lies in its adaptability: mRNA platforms can be reprogrammed rapidly to address new pathogens or variants, offering unparalleled flexibility in global health response. This makes mRNA vaccines not only innovative but also a critical defense strategy in an era of evolving infectious diseases.

Monoclonal Antibodies

Unlike traditional vaccines that stimulate the body to generate its own antibodies, monoclonal antibody therapies provide immediate protection by introducing lab-designed antibodies directly into the system. This approach is particularly effective for individuals who cannot yet receive vaccines, such as infants, or in situations where no vaccine currently exists. Healthmat Pharmaceuticals is leveraging monoclonal antibody technology to bridge vital gaps in immunity. By offering rapid, targeted protection, these therapies can be life-saving during outbreaks or for high-risk populations. Moreover, they can complement vaccines by offering a layer of defense until long-term immunity is established.

Adjuvanted Vaccines

Adjuvants are substances added to vaccines to boost the immune response, enhancing their effectiveness and durability. They not only make vaccines work better but also allow lower doses of antigen to be used, which increases vaccine availability during periods of high demand, such as global outbreaks. At Healthmat Pharmaceuticals, we develop our own proprietary adjuvants and collaborate with partners to create innovative combinations. For instance, our COVID-19 vaccine candidate demonstrates how pairing an effective antigen with a well-designed adjuvant can enhance protection and widen accessibility, particularly in times of urgent global need.

Harnessing Data Science for Vaccine Innovation

The most important step in vaccine development is understanding the enemy—pathogens—and their evolving strategies to evade immune defenses. At Healthmat Pharmaceuticals, we deploy machine learning and artificial intelligence (AI) to analyze massive datasets, track genetic changes in microbes, and predict their vulnerabilities. This data-driven approach enables us to design vaccines with greater accuracy and speed. By staying ahead of pathogen evolution, we increase the likelihood of developing long-lasting and broadly protective vaccines, helping us outmaneuver even the most adaptable infectious agents.

Simplifying Immunization Through Combination Vaccines

Vaccination should be effective and accessible. That’s why Healthmat Pharmaceuticals is a world leader in pediatric combination vaccines—single formulations that protect against multiple diseases at once. These innovations make immunization easier, improve adherence to vaccination schedules, and sustain high levels of community protection. Behind every combination vaccine lies complex science. Each antigen must remain stable, effective, and non-reactive with others in the formulation. Our teams ensure that these formulations meet rigorous standards, delivering safe, reliable protection for children worldwide while simplifying healthcare delivery.

Get a Quote

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Redefining Possibilities in Medicine

We believe the future of healthcare lies in daring to explore new frontiers. By pushing the limits of immunology, oncology, neurology, and rare disease research, Healthmat Pharmaceuticals is rewriting what is possible in patient treatment and recovery.

BLOG SECTION

Insights & Articles

We believe the future of medicine lies in unlocking the full potential of the immune system. For over five decades, our commitment to scientific excellence has helped shape the way the world understands and treats disease — from delivering the first polio vaccine to advancing breakthrough therapies that have transformed countless lives.

VACCINES

Innovation for Disease Prevention and Control

Vaccines: Pioneering Innovation for Global Health Protection

Types of Vaccines We Develop

Live-Attenuated Vaccines

Inactivated Vaccines

Recombinant Protein Vaccines

Polysaccharide-Based Vaccines

mRNA Vaccines

Monoclonal Antibodies

Adjuvanted Vaccines

Harnessing Data Science for Vaccine Innovation

Simplifying Immunization Through Combination Vaccines

Get a Quote

Redefining Possibilities in Medicine

BLOG SECTION

Insights & Articles

Beyond Medicine

Breaking Barriers

From Lab to Life

Signup our newsletter to get update information, news, insight or promotions.

Company

Our Sciences

Reach Us